189 related articles for article (PubMed ID: 9030365)
1. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues.
Famularo G; Moretti S; Marcellini S; Trinchieri V; Tzantzoglou S; Santini G; Longo A; De Simone C
AIDS; 1997 Feb; 11(2):185-90. PubMed ID: 9030365
[TBL] [Abstract][Full Text] [Related]
2. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.
Moore RD; Wong WM; Keruly JC; McArthur JC
AIDS; 2000 Feb; 14(3):273-8. PubMed ID: 10716503
[TBL] [Abstract][Full Text] [Related]
3. Peripheral neuropathy during stavudine-didanosine antiretroviral therapy.
Reliquet V; Mussini JM; Chennebault JM; Lafeuillade A; Raffi F
HIV Med; 2001 Apr; 2(2):92-6. PubMed ID: 11737385
[TBL] [Abstract][Full Text] [Related]
4. Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical Group 175/801 Study Team.
Simpson DM; Katzenstein DA; Hughes MD; Hammer SM; Williamson DL; Jiang Q; Pi JT
AIDS; 1998 Dec; 12(18):2425-32. PubMed ID: 9875580
[TBL] [Abstract][Full Text] [Related]
5. The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.
Arenas-Pinto A; Bhaskaran K; Dunn D; Weller IV
Antivir Ther; 2008; 13(2):289-95. PubMed ID: 18505180
[TBL] [Abstract][Full Text] [Related]
6. ddI and d4T plus protease inhibitors.
GMHC Treat Issues; 1996 Nov; 10(11):8-9. PubMed ID: 11364012
[TBL] [Abstract][Full Text] [Related]
7. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
Kuritzkes DR; Marschner I; Johnson VA; Bassett R; Eron JJ; Fischl MA; Murphy RL; Fife K; Maenza J; Rosandich ME; Bell D; Wood K; Sommadossi JP; Pettinelli C
AIDS; 1999 Apr; 13(6):685-94. PubMed ID: 10397563
[TBL] [Abstract][Full Text] [Related]
8. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection.
Simpson DM; Tagliati M
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jun; 9(2):153-61. PubMed ID: 7749792
[TBL] [Abstract][Full Text] [Related]
9. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management.
Moyle GJ; Sadler M
Drug Saf; 1998 Dec; 19(6):481-94. PubMed ID: 9880091
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC).
Dalakas MC; Semino-Mora C; Leon-Monzon M
Lab Invest; 2001 Nov; 81(11):1537-44. PubMed ID: 11706061
[TBL] [Abstract][Full Text] [Related]
11. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
12. Peripheral neuropathy and antiretroviral drugs.
Dalakas MC
J Peripher Nerv Syst; 2001 Mar; 6(1):14-20. PubMed ID: 11293802
[TBL] [Abstract][Full Text] [Related]
13. Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients.
Dragovic G; Jevtovic D
Antivir Chem Chemother; 2003 Sep; 14(5):281-4. PubMed ID: 14694991
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study.
Hulgan T; Haas DW; Haines JL; Ritchie MD; Robbins GK; Shafer RW; Clifford DB; Kallianpur AR; Summar M; Canter JA
AIDS; 2005 Sep; 19(13):1341-9. PubMed ID: 16103764
[TBL] [Abstract][Full Text] [Related]
15. [Antiretroviral treatment. Present and future of the combinations].
Gatell-Artigas JM
Rev Neurol; 1996 Dec; 24(136):1627-31. PubMed ID: 9064189
[TBL] [Abstract][Full Text] [Related]
16. Didanosine (ddl) and stavudine (d4T): absence of peripheral neurotoxicity in rabbits.
Warner WA; Bregman CL; Comereski CR; Arezzo JC; Davidson TJ; Knupp CA; Kaul S; Durham SK; Wasserman AJ; Frantz JD
Food Chem Toxicol; 1995 Dec; 33(12):1047-50. PubMed ID: 8847000
[TBL] [Abstract][Full Text] [Related]
17. Nucleoside analogues and mitochondrial toxicity.
Fleischer R; Boxwell D; Sherman KE
Clin Infect Dis; 2004 Apr; 38(8):e79-80. PubMed ID: 15095236
[TBL] [Abstract][Full Text] [Related]
18. [Weak antiviral effect of changing two nucleoside analogues combined with antiretroviral agents. 3TC and d4T after ZDU and ddi or ddc].
Rey D; Schmitt AC; Schmitt MP; Partisani M; Nicolle M; Kempf-Durepaire G; Krantz V; Lang JM
Presse Med; 1998 Feb; 27(8):360. PubMed ID: 9768003
[No Abstract] [Full Text] [Related]
19. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
Moore RD; Keruly JC; Chaisson RE
AIDS; 2001 Mar; 15(5):617-20. PubMed ID: 11316999
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of stavudine.
Rana KZ; Dudley MN
Clin Pharmacokinet; 1997 Oct; 33(4):276-84. PubMed ID: 9342503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
